[144] BELITE BIO, INC SEC Filing

Rhea-AI Filing Summary

Belite Bio, Inc. (BLTE) Form 144 shows an insider sale notice for 96,950 American Depositary Shares (ADS), each representing one ordinary share, scheduled approximately for 09/18/2025 through J.P. Morgan Securities LLC. The filing reports an aggregate market value of $7,077,350 based on the shares to be sold, against 32,833,402 shares outstanding. The ADS were acquired on 12/31/2021 via an employee stock option exercise and were paid for in cash. The filer, identified as Yu‑Hsin Lin (c/o Belite Bio), previously sold small blocks of ADS on 08/07/2025 (269 ADS, $19,906) and 08/12/2025 (700 ADS, $51,856).

The filer attests they are not aware of any undisclosed material adverse information and the notice includes the usual certification language required by Rule 144.

Positive

• Full acquisition disclosure: acquisition date and nature (employee stock option exercise on 12/31/2021) are provided
• Brokered sale through a major firm: execution via J.P. Morgan Securities LLC indicates standard market procedures
• Prior recent dispositions disclosed: August 2025 sales are listed, supporting Rule 144 aggregation requirements

Negative

• Large dollar value: the planned sale totals about $7,077,350, which is material in cash terms even if small versus total shares outstanding
• No 10b5‑1 plan date indicated: the form does not state reliance on a pre‑arranged trading plan, which may raise timing questions (only factual absence is reported in the filing)

Insights

Securities Analyst

TL;DR: Routine insider sale of existing employee-option shares; size modest relative to total float but material in value.

The filing documents a planned sale of 96,950 ADS worth about $7.08 million. These shares were acquired by exercise of employee options in 2021 and the sale is being routed through a major broker, indicating a standard market sale rather than a secondary offering. Relative to the company's outstanding share count of 32.83 million, the block represents roughly 0.30% of outstanding shares, so dilution/market impact is limited but the dollar value is non‑trivial. Prior small disposals in August 2025 are disclosed, consistent with staged selling. No earnings or operational data are included.

Compliance/Risk Analyst

TL;DR: Filing appears compliant with Rule 144 formalities and includes the required attestation.

The notice lists acquisition details (employee stock option exercise on 12/31/2021), payment in cash, broker information, and prior recent sales, which supports aggregation disclosures under Rule 144. The seller’s attestation that they are unaware of undisclosed material adverse information is present, and the expected sale date and aggregate market value are provided. There is no indication in the document of 10b5‑1 plan reliance or additional escrow/transfer arrangements. Based solely on the form, this is a routine disclosure; any compliance risk would require information outside this filing.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares, each representing one ordinary share	J.P. Morgan Securities LLC 390 Madison Avenue, 6th Floor New York NY 10017	96950	7077350	32833402	09/18/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
American Depositary Shares, each representing one ordinary share	12/31/2021	Employee Stock Option Exercise	Issuer			96950	12/31/2021	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Yu-Hsin Lin C/o Belite Bio, Inc. 12750 High Bluff Drive, Suite 475 San Diego CA 92130	American Depositary Shares, each representing one ordinary share	08/07/2025	269	19906
Yu-Hsin Lin C/o Belite Bio, Inc. 12750 High Bluff Drive, Suite 475 San Diego CA 92130	American Depositary Shares, each representing one ordinary share	08/12/2025	700	51856

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the BLTE Form 144 disclose about the planned sale on 09/18/2025?

The filing notifies a proposed sale of 96,950 ADS (each ADS = one ordinary share) scheduled for 09/18/2025 through J.P. Morgan Securities LLC, with an aggregate market value of $7,077,350.

Who is the seller named in the BLTE Form 144?

The seller is listed as Yu‑Hsin Lin, identified in the filing as c/o Belite Bio, Inc., with prior small ADS sales in August 2025.

How and when were the shares being sold acquired?

The ADS were acquired on 12/31/2021 via an employee stock option exercise and payment was made in cash on that date.

How large is the planned sale versus total shares outstanding?

The 96,950 ADS represent about 0.30% of the reported 32,833,402 shares outstanding (simple proportion based on ADS count).

Does the Form 144 state the seller knows of any undisclosed material information?

The filer signs the standard attestation representing they do not know of any material adverse information about the issuer that has not been publicly disclosed.